TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+head and neck cancer cells

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

Monoclonal Antibody Therapy of Pancreatic Cancer With Cetuximab

(2012) Eric Luedke et al.   JOURNAL OF IMMUNOTHERAPY

Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes

(2011) Michael S. Leibowitz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Defective NF- B Signaling in Metastatic Head and Neck Cancer Cells Leads to Enhanced Apoptosis by Double-Stranded RNA

(2011) N. Umemura et al.   CANCER RESEARCH

Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

(2011) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection

(2011) I. Jelinek et al.   JOURNAL OF IMMUNOLOGY

Toll-like Receptor 3–Mediated Suppression of TRAMP Prostate Cancer Shows the Critical Role of Type I Interferons in Tumor Immune Surveillance

(2010) Arnold I. Chin et al.   CANCER RESEARCH

TLR3 agonists as immunotherapeutic agents

(2010) Christopher F Nicodemus et al.   Immunotherapy

Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape

(2010) Robert L. Ferris et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

(2010) Hideho Okada et al.   JOURNAL OF CLINICAL ONCOLOGY

TLR3 and Rig-Like Receptor on Myeloid Dendritic Cells and Rig-Like Receptor on Human NK Cells Are Both Mandatory for Production of IFN-  in Response to Double-Stranded RNA

(2010) I. Perrot et al.   JOURNAL OF IMMUNOLOGY

A Real-Time PCR Assay for the Simultaneous Detection of Functional N284I and L412F Polymorphisms in the Human Toll-Like Receptor 3 Gene

(2010) Robert A. Brown et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Immune Modulation with Interleukin-21

(2009) Neela S. Bhave et al.   Annals of the New York Academy of Sciences

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

(2009) Andrés López-Albaitero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PolyI:C plus IL-2 or IL-12 induce IFN-γ production by human NK cellsviaautocrine IFN-β

(2009) Dorothée Duluc et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma

(2009) Kazumasa Hiroishi et al.   JOURNAL OF GASTROENTEROLOGY

Maturation Pathways of Dendritic Cells Determine TAP1 and TAP2 Levels and Cross-presenting Function

(2009) Andrés López-Albaitero et al.   JOURNAL OF IMMUNOTHERAPY

Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients

(2009) Pedro A. Andrade Filho et al.   JOURNAL OF IMMUNOTHERAPY

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck

(2009) William N William et al.   Nature clinical practice. Oncology

Recognition of viral single-stranded RNA by Toll-like receptors☆

(2008) S DIEBOLD   ADVANCED DRUG DELIVERY REVIEWS

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

(2008) Aruna Mani et al.   BREAST CANCER RESEARCH AND TREATMENT

Sensing of Viral Infection and Activation of Innate Immunity by Toll-Like Receptor 3

(2008) E. Vercammen et al.   CLINICAL MICROBIOLOGY REVIEWS

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas

(2008) Nicholas Butowski et al.   JOURNAL OF NEURO-ONCOLOGY

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)

(2008) Nicholas Butowski et al.   JOURNAL OF NEURO-ONCOLOGY

The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine

(2008) C. Trumpfheller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA